{"id":2766,"date":"2026-02-27T22:13:46","date_gmt":"2026-02-28T03:13:46","guid":{"rendered":"https:\/\/lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/"},"modified":"2026-02-27T22:51:45","modified_gmt":"2026-02-28T03:51:45","password":"","slug":"screening-of-neoantigen-hla-complexes","status":"publish","type":"docs","link":"https:\/\/www.lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/","title":{"rendered":"Screening of Neoantigen HLA Complexes"},"content":{"rendered":"<p>Mutated peptides, known as neoantigens, derived from a patient&#8217;s cancer genome can be targeted by T-cell immunity. However, identifying which peptides can be presented by MHC molecules and stimulate T cells has proven challenging. Existing algorithms can predict MHC binding but struggle to account for the half-lives of these complexes (a critical immunological parameter called kinetic stability). Enhancing our ability to determine the true stability of neoantigen peptide\/MHC complexes is crucial, as only a small fraction of peptides in current vaccines effectively trigger CD8+ T-cell responses.<\/p>\n<p>A study utilized a rapid, high-throughput approach to experimentally measure peptide\/HLA thermal stability on a scale needed for analyzing neoantigens from thousands of patients. By combining UV-cleavable peptide\/HLA class I complexes with differential scanning fluorimetry, the Tm values of neoantigen complexes were determined. These Tm values were accurate, reproducible, and directly proportional to the complexes&#8217; half-lives. When analyzing known HLA-A2\u2013restricted immunogenic peptides, Tm values correlated more strongly with immunogenicity than algorithm-predicted binding affinities. Using temperature stability information can help select neoantigens for cancer vaccines, focusing on mutated peptides most likely to be expressed on the cell surface.<\/p>\n<p><strong>Tm&nbsp;analysis of HLA-A2 complexes containing immunogenic neoantigen peptides<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Gene<\/th>\n<th>Sequence<\/th>\n<th>&nbsp;<\/th>\n<th>Tm&nbsp;(\u00b0C)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u2003<em>ME-1<\/em>&nbsp;<\/td>\n<td>FLDEFMEGV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>63.2 \u00b1 0.4&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>FNDC3B<\/em>&nbsp;<\/td>\n<td>VVMSWAPPV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>61.6 \u00b1 0.6&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>PRDX5<\/em>&nbsp;<\/td>\n<td>LLLDDLLVSI&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>55.3 \u00b1 0.7&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>GAS7<\/em>&nbsp;<\/td>\n<td>SLADEAEVYL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>59.2 \u00b1 0.7&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>KIAA0223<\/em>&nbsp;<\/td>\n<td>VLHDDLLEA&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>59.7 \u00b1 0.5&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>GAPDH<\/em>&nbsp;<\/td>\n<td>GIVEGLITTV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>58.5 \u00b1 0.6&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>HSP70<\/em>&nbsp;<\/td>\n<td>SLFEGIDIYT&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>59.8 \u00b1 0.6&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>ACTININ<\/em>&nbsp;<\/td>\n<td>FIASNGVKLV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>56.9 \u00b1 0.5&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>HAUS3<\/em>&nbsp;<\/td>\n<td>ILNAMIAKI&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>56.9 \u00b1 0.2&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>CSNK1A1<\/em>&nbsp;<\/td>\n<td>GLFGDIYLAI&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>52.6 \u00b1 0.6&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>CLPP<\/em>&nbsp;<\/td>\n<td>ILDKVLVHL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>57.1 \u00b1 0.4&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>CDK4<\/em>&nbsp;<\/td>\n<td>ACDPHSGHFV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>59.9 \u00b1 0.3&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>AHNAK<\/em>&nbsp;<\/td>\n<td>FMPDFDLHL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>60.1 \u00b1 0.2&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>SRPX<\/em>&nbsp;<\/td>\n<td>TLWCSPIKV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>63.7 \u00b1 0.1&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>COL18A1<\/em>&nbsp;<\/td>\n<td>VLLGVKLFGV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>60.9 \u00b1 0.3&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>ERBB2<\/em>&nbsp;<\/td>\n<td>ALIHHNTYL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>59.4 \u00b1 0.5&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>TEAD1<\/em>&nbsp;<\/td>\n<td>VLENFTIFLV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>48.2 \u00b1 0.2&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>TEAD1<\/em>&nbsp;<\/td>\n<td>SVLENFTIFL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>55.8 \u00b1 0.2&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>NSDHL<\/em>&nbsp;<\/td>\n<td>ILTGLNYEV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>61.4 \u00b1 0.1&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>GANAB<\/em>&nbsp;<\/td>\n<td>ALYGFVPVL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>61.7 \u00b1 0.2&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>CDC37L1<\/em>&nbsp;<\/td>\n<td>FLSDHLYLV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>61.8 \u00b1 0.1&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>FLNA<\/em>&nbsp;<\/td>\n<td>HIAKSLFEV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>56.4 \u00b1 0.4&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>SPOP<\/em>&nbsp;<\/td>\n<td>FLLDEAIGL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>60.7 \u00b1 0.1&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>ACPP<\/em>&nbsp;<\/td>\n<td>VLAKKLKFV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>56.8 \u00b1 0.7&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>DCAKD<\/em>&nbsp;<\/td>\n<td>LLHTELERFL&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>42.9 \u00b1 0.2&nbsp;<\/td>\n<\/tr>\n<tr>\n<td>\u2003<em>CIT<\/em>&nbsp;<\/td>\n<td>TLLSQVNKV&nbsp;<\/td>\n<td>&nbsp;<\/td>\n<td>53.2 \u00b1 0.3&nbsp;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- liveagent_urlcode:971533 liveagent_entry_id: --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mutated peptides, known as neoantigens, derived from a patient&#8217;s cancer genome can be targeted by T-cell immunity. However, identifying which peptides can be presented by MHC molecules and stimulate T cells has proven challenging. Existing algorithms can predict MHC binding &hellip; <a href=\"https:\/\/www.lifetein.com\/blog\/docs\/screening-of-neoantigen-hla-complexes\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_crdt_document":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"doc_category":[331],"doc_tag":[],"class_list":["post-2766","docs","type-docs","status-publish","hentry","doc_category-technical-protocols"],"aioseo_notices":[],"year_month":"2026-04","word_count":363,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"lifetein","author_nicename":"new_blog","author_url":"https:\/\/www.lifetein.com\/blog\/author\/new_blog\/"},"doc_category_info":[{"term_name":"Technical Protocols","term_url":"https:\/\/www.lifetein.com\/blog\/docs-category\/technical-protocols\/"}],"doc_tag_info":[],"_links":{"self":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs"}],"about":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/types\/docs"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/comments?post=2766"}],"version-history":[{"count":1,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2766\/revisions"}],"predecessor-version":[{"id":2803,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2766\/revisions\/2803"}],"wp:attachment":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media?parent=2766"}],"wp:term":[{"taxonomy":"doc_category","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/doc_category?post=2766"},{"taxonomy":"doc_tag","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/doc_tag?post=2766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}